Previous 10 | Next 10 |
Company Overview MeiraGTx ( MGTX ) is a clinical-stage gene therapy company targeting serious conditions with no existing curative options or even acceptable therapeutic approaches. It has four clinical-stage programs for ocular conditions, one for Parkinson's disease, and one for radiatio...
MeiraGTx (NASDAQ: MGTX ) : Q2 GAAP EPS of -$0.69 misses by $0.14 . More news on: MeiraGTx Holdings plc, Earnings news and commentary, Healthcare stocks news, Read more ...
- Positive initial data from Phase 1/2 clinical trial of AAV-RPGR for the treatment of XLRP recently presented - AAV-RPGR to advance into Phase 3 Lumeos clinical trial - Expands manufacturing capabilities with new facilities in Ireland LONDON and NEW YORK, Aug. 06, 2020 (G...
LONDON and NEW YORK, Aug. 05, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced the appointment of Robert K. Zeldin, M.D. as chief medical officer (CMO). A clinical immunologist by tr...
MeiraGTx reports encouraging data for ocular gene therapy MeiraGTx ( MGTX ) announced initial data from its ongoing clinical trial of AAV-RPGR, for treating patients with X-linked retinitis pigmentosa (XLRP) with genetically confirmed variants in the RPGR gene. The dose escalation phase ...
RumbleON (NASDAQ: RMBL ) +117% on pilot program with CarGurus. More news on: RumbleON, Inc., Verona Pharma plc, Applied DNA Sciences, Inc., Stocks on the move, , Read more ...
Johnson & Johnson (NYSE: JNJ ) unit Janssen Pharmaceutical Companies reports positive six-month data from a Phase 1/2 clinical trial evaluating gene therapy AAV-RPGR in patients with X-linked retinitis pigmentosa , a group of inherited retinal disorders characterized by progressiv...
• Data being presented at the American Society of Retina Specialists (ASRS) 2020 Virtual Annual Meeting • Significant improvements demonstrated after treatment in Phase 1/2 clinical trial • Based on encouraging safety and efficacy profile,...
LONDON and NEW YORK, May 26, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that its 2020 Annual General Meeting of Shareholders scheduled for Tuesday, June 2, 2020 at 10:00 a.m. ET,...
MeiraGTx (NASDAQ: MGTX ): Q1 GAAP EPS of -$0.43 in-line. More news on: MeiraGTx Holdings plc, Earnings news and commentary, Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
MeiraGTx Holdings plc Company Name:
MGTX Stock Symbol:
NASDAQ Market:
MeiraGTx Holdings plc Website:
- Positive data from the Phase 1 AQUAx study in radiation-induced xerostomia (RIX) presented in an oral session at the American Academy of Oral Medicine 2024 annual meeting (AAOM) April 17-20, 2024 - Received $50 million milestone following initiation of the extension study for the Ph...
LONDON and NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced the Company gave an oral presentation at the American Academy of Oral Medicine Annual Conference, being held f...
2024-04-17 00:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...